JP2014525470A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014525470A5 JP2014525470A5 JP2014528965A JP2014528965A JP2014525470A5 JP 2014525470 A5 JP2014525470 A5 JP 2014525470A5 JP 2014528965 A JP2014528965 A JP 2014528965A JP 2014528965 A JP2014528965 A JP 2014528965A JP 2014525470 A5 JP2014525470 A5 JP 2014525470A5
- Authority
- JP
- Japan
- Prior art keywords
- propyl
- phenyl
- methanesulfonyl
- piperidine hydrochloride
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YGRHOYQMBLLGEV-UHFFFAOYSA-N 4-(3-methylsulfonylphenyl)-1-propylpiperidine;hydrochloride Chemical compound Cl.C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGRHOYQMBLLGEV-UHFFFAOYSA-N 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 5
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- -1 Sulfonyl-phenyl Chemical group 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229960003638 dopamine Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 claims 3
- ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201170496 | 2011-09-07 | ||
| DKPA201170496 | 2011-09-07 | ||
| US201161533550P | 2011-09-12 | 2011-09-12 | |
| US61/533,550 | 2011-09-12 | ||
| PCT/EP2012/067371 WO2013034622A1 (en) | 2011-09-07 | 2012-09-06 | Polymorphic form of pridopidine hydrochloride |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017107986A Division JP2017206516A (ja) | 2011-09-07 | 2017-05-31 | プリドピジン塩酸塩の新規な多形形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014525470A JP2014525470A (ja) | 2014-09-29 |
| JP2014525470A5 true JP2014525470A5 (enExample) | 2015-11-05 |
| JP6189299B2 JP6189299B2 (ja) | 2017-08-30 |
Family
ID=47831564
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014528965A Expired - Fee Related JP6189299B2 (ja) | 2011-09-07 | 2012-09-06 | プリドピジン塩酸塩の新規な多形形態 |
| JP2017107986A Withdrawn JP2017206516A (ja) | 2011-09-07 | 2017-05-31 | プリドピジン塩酸塩の新規な多形形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017107986A Withdrawn JP2017206516A (ja) | 2011-09-07 | 2017-05-31 | プリドピジン塩酸塩の新規な多形形態 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9006445B2 (enExample) |
| EP (1) | EP2753603B1 (enExample) |
| JP (2) | JP6189299B2 (enExample) |
| KR (1) | KR20140075703A (enExample) |
| CN (1) | CN103958469B (enExample) |
| AU (1) | AU2012306386B2 (enExample) |
| BR (1) | BR112014005389A8 (enExample) |
| CA (1) | CA2847736A1 (enExample) |
| EA (1) | EA023462B1 (enExample) |
| ES (1) | ES2639052T3 (enExample) |
| IL (1) | IL231149A0 (enExample) |
| MX (1) | MX343620B (enExample) |
| WO (1) | WO2013034622A1 (enExample) |
| ZA (1) | ZA201402492B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| MX2009011020A (es) | 2007-04-12 | 2009-10-30 | Nsab Af Neurosearch Sweden Ab | Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| EP2787997A4 (en) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| BR112014024672A8 (pt) | 2012-04-04 | 2018-04-03 | Ivax Int Gmbh | Composições farmacêuticas para terapia de combinação |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CA2913781C (en) | 2013-06-21 | 2022-05-10 | Teva Pharmaceutical Industries Ltd. | Use of pridopidine for treating huntington's disease |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| WO2016106142A1 (en) | 2014-12-22 | 2016-06-30 | Teva Pharmaceuticals International Gmbh | L-tartrate salt of pridopidine |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| EP3854785A1 (en) | 2015-02-25 | 2021-07-28 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| EP3419622B1 (en) | 2016-02-24 | 2024-03-06 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| CN110012661A (zh) | 2016-08-24 | 2019-07-12 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗肌张力障碍的用途 |
| IL311081A (en) | 2016-08-24 | 2024-04-01 | Prilenia Neurotherapeutics Ltd | Use of pyridofidine to treat functional decline |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| ES2972205T3 (es) | 2017-01-20 | 2024-06-11 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento del síndrome x frágil |
| EP3357909A1 (en) | 2017-02-02 | 2018-08-08 | Sandoz AG | Crystalline 4-[3-(methylsulfonyl)phenyl]-1-propyl-piperidine |
| HUE061505T2 (hu) | 2017-08-14 | 2023-07-28 | Prilenia Neurotherapeutics Ltd | Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel |
| JP2020532517A (ja) | 2017-08-30 | 2020-11-12 | プリレニア ニューロセラピューティクス リミテッド | 高濃度プリドピジン製剤 |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| CA3075020C (en) | 2017-09-08 | 2021-12-07 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| JP7585561B2 (ja) | 2019-02-04 | 2024-11-19 | プリレニア ニューロセラピューティクス リミテッド | パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン |
| AU2020243692B2 (en) | 2019-03-15 | 2023-03-02 | Prilenia Neurotherapeutics Ltd. | Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine |
| CN116472043A (zh) | 2020-10-20 | 2023-07-21 | 普瑞尼亚神经治疗有限公司 | 普利多匹定和类似物用于治疗焦虑和抑郁的用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| GB0329236D0 (en) * | 2003-12-17 | 2004-01-21 | Arakis Ltd | Crystalline forms of (+)- and (-)- erthro-mefloquine hydrochloride |
| CA2569843A1 (en) | 2004-06-08 | 2005-12-22 | A. Carlsson Research Ab | New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
| ES2659577T3 (es) | 2004-10-13 | 2018-03-16 | Teva Pharmaceuticals International Gmbh | Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina |
| SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| TW200804241A (en) * | 2006-02-24 | 2008-01-16 | Novartis Ag | New salt |
| MX2009011020A (es) | 2007-04-12 | 2009-10-30 | Nsab Af Neurosearch Sweden Ab | Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares. |
| US20100197712A1 (en) | 2007-06-18 | 2010-08-05 | Arvid Carlsson | Use of dopamine stabilizers |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| EP2787997A4 (en) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| BR112014024672A8 (pt) | 2012-04-04 | 2018-04-03 | Ivax Int Gmbh | Composições farmacêuticas para terapia de combinação |
| MX2015003812A (es) | 2012-09-27 | 2015-07-17 | Teva Pharma | Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington. |
| US20150209346A1 (en) | 2012-09-27 | 2015-07-30 | Teva Pharmaceutical Industries, Ltd. | Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
-
2012
- 2012-09-06 MX MX2014002731A patent/MX343620B/es active IP Right Grant
- 2012-09-06 BR BR112014005389A patent/BR112014005389A8/pt not_active IP Right Cessation
- 2012-09-06 EP EP12755869.0A patent/EP2753603B1/en active Active
- 2012-09-06 JP JP2014528965A patent/JP6189299B2/ja not_active Expired - Fee Related
- 2012-09-06 AU AU2012306386A patent/AU2012306386B2/en not_active Ceased
- 2012-09-06 EA EA201490569A patent/EA023462B1/ru not_active IP Right Cessation
- 2012-09-06 CA CA 2847736 patent/CA2847736A1/en not_active Abandoned
- 2012-09-06 KR KR20147009105A patent/KR20140075703A/ko not_active Ceased
- 2012-09-06 ES ES12755869.0T patent/ES2639052T3/es active Active
- 2012-09-06 WO PCT/EP2012/067371 patent/WO2013034622A1/en not_active Ceased
- 2012-09-06 CN CN201280043794.9A patent/CN103958469B/zh active Active
- 2012-09-06 US US14/342,253 patent/US9006445B2/en active Active
-
2014
- 2014-02-25 IL IL231149A patent/IL231149A0/en unknown
- 2014-04-04 ZA ZA2014/02492A patent/ZA201402492B/en unknown
-
2017
- 2017-05-31 JP JP2017107986A patent/JP2017206516A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514060A5 (enExample) | ||
| PH12016501439B1 (en) | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors | |
| JP2015522589A5 (enExample) | ||
| JP2017527578A5 (enExample) | ||
| JP2016503010A5 (enExample) | ||
| RU2014105881A (ru) | Ансольваты солей норибогаина | |
| JP2013237682A5 (enExample) | ||
| JP2012176975A5 (enExample) | ||
| EP4241772A3 (en) | Process for the preparation of compounds useful for treating spinal muscular atrophy | |
| EA201401150A1 (ru) | Аминоиндолилзамещенные имидазолпиримидины и их применение в качестве лекарственных средств | |
| NZ711424A (en) | Pyridine derivatives as soft rock inhibitors | |
| CN103717571B8 (zh) | 9‑氨基甲基取代的四环素类化合物 | |
| MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
| WO2014059232A3 (en) | Substituted spiropiperidinyl compounds useful as gpr120 agonists | |
| JP2017524733A5 (enExample) | ||
| EA201270205A1 (ru) | Фармацевтические композиции для лечения рака и других заболеваний и нарушений состояния здоровья | |
| EA201300436A1 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| TN2016000511A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| JP2014530818A5 (enExample) | ||
| IN2012DN03042A (enExample) | ||
| GB201302704D0 (en) | Therapeutic compounds | |
| PH12018502445A1 (en) | Compositions and methods for treating negative symptoms in non-schizophrenic patients | |
| TN2013000533A1 (en) | Topical ophthalmological pharmaceutical composition containing regorafenib | |
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| JP2016172741A5 (enExample) |